Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

BACKGROUND: In breast cancer endocrine therapy, post-therapy Ki-67 assay of biopsy material predicts recurrence-free survival but is invasive and prone to sampling error. [(18)F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) has shown an early agonist or ‘flare’ response to tamoxifen an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurland, Brenda F, Gadi, Vijayakrishna K, Specht, Jennifer M, Allison, Kimberly H, Livingston, Robert B, Rodler, Eve T, Peterson, Lanell M, Schubert, Erin K, Chai, Xiaoyu, Mankoff, David A, Linden, Hannah M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444390/
https://www.ncbi.nlm.nih.gov/pubmed/22731662
http://dx.doi.org/10.1186/2191-219X-2-34

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444390/
https://www.ncbi.nlm.nih.gov/pubmed/22731662
http://dx.doi.org/10.1186/2191-219X-2-34

Ejemplares similares